drugset / Trial / NCT05602597
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Non-randomizedParallel-groupOpen-labelOther
Summary
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
Timeline
- Start
- 2022-06-01
- Primary completion
- 2022-08-06
- Completion
- 2022-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluconazole | Small molecule | 200 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Rabeprazole | Small molecule | 40 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |